CRISPR Therapeutics AG

Report azionario NasdaqGM:CRSP

Capitalizzazione di mercato: US$5.8b

CRISPR Therapeutics Crescita futura

Criteri Future verificati 2/6

CRISPR Therapeutics prevede che gli utili e i ricavi cresceranno rispettivamente di 64.7% e 65.2% all'anno. Si prevede che l'EPS crescerà di 64% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -56.2% in 3 anni.

Informazioni chiave

64.7%

Tasso di crescita degli utili

63.97%

Tasso di crescita dell'EPS

Biotechs crescita degli utili25.1%
Tasso di crescita dei ricavi65.2%
Rendimento futuro del capitale proprio-56.18%
Copertura analitica

Good

Ultimo aggiornamento03 Jul 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Jul 03

Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment

Summary Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy’s robust clinical efficacy, global approvals, and strong safety profile support its multibillion-dollar potential, despite initial slow commercial uptake due to complex treatment and high cost. CRSP’s pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases, aiming to further simplify and expand gene therapy applications. With pediatric approval, CRSP is positioned for accelerated revenue growth; patient pool expansion and technical advances could drive significant upside toward historic share price highs. Read the full article on Seeking Alpha
Articolo di analisi • Jun 20

CRISPR Therapeutics (CRSP) Stock Could Be 69.5% Below Fair Value After Recent Gains

CRISPR Therapeutics (CRSP) shares have caught investor attention after recent trading, with the stock closing at US$54.09. That move comes alongside solid short term returns over the past week and month. See our latest analysis for CRISPR Therapeutics. Looking beyond the latest move, CRISPR Therapeutics shows building short term momentum, with a 7 day share price return of 8.61% and 30 day share price return of 8.40%, set against a 1 year total shareholder return of 22.24% but a weaker 5 year...
Seeking Alpha • Mar 14

CRISPR Therapeutics: An Uninspiring Start For Casgevy

Summary CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from Casgevy yet, but $35M in collaboration revenue from Vertex and a net loss of $37.311M. Despite pioneering technology, CRISPR faces slow gene therapy adoption and stiff competition in CAR-T therapies, with no exciting pipeline developments. CRISPR remains a cautious "Hold" within a barbell portfolio, pending momentum from Casgevy's launch and clinical trial success outside rare diseases. Read the full article on Seeking Alpha
Seeking Alpha • Feb 13

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Summary Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securities. Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes. The company is focused on easing pre-conditioning regimes and developing allogeneic and in-vivo therapies, which could exponentially increase the addressable market and drive future revenue growth. With major data readouts expected in 2025 and potential Casgevy revenues, CRSP stock remains a compelling investment despite current share price stasis. Read the full article on Seeking Alpha
Seeking Alpha • Jan 16

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Summary CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic partnership with Vertex Pharmaceuticals has provided stability and resources, leading to the first FDA-approved CRISPR-based gene editing treatment, Casgevy. Editas' discontinuation of its SCD and TDT program and significant layoffs highlight its precarious position compared to CRISPR's better financial health and strategic advantages. CRISPR's current valuation is attractive, with $1.9 billion in cash and expected revenue from Casgevy, making it a speculative but compelling buy. Read the full article on Seeking Alpha
Seeking Alpha • Dec 29

Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025

Summary Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024. Despite a slow roll-out, Casgevy's increasing patient demand, reimbursement agreements, and positive long-term efficacy data support a bright revenue outlook and potential profitability by 2028. Crispr's robust pipeline, including CTX310 and CTX320 for cardiovascular diseases, holds blockbuster potential, with top-line results expected in 2025, enhancing long-term growth prospects. With $1.9 billion in cash, Crispr has financial stability for at least 3.6 years, supporting ongoing development without needing to raise capital, making it a "buy" for high-risk tolerant investors. Read the full article on Seeking Alpha
Seeking Alpha • Nov 11

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

Summary CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a strong cash position and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies. Vertex's partnership and investment highlight Casgevy's potential, but long-term success hinges on improving treatment processes and securing further drug approvals. With nearly $2bn in cash and a promising pipeline, CRISPR Therapeutics remains a compelling long-term investment - I'm anticipating significant developments by 2025. Read the full article on Seeking Alpha
Seeking Alpha • Oct 28

Crispr Therapeutics: Poised For A Major Turnaround

Summary Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline. Despite competition, Crispr's first-mover advantage, strategic partnerships, and robust pipeline create a durable moat, making it a compelling investment in the biotech sector. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Summary Casgevy is now active across 35 Advanced Treatment Centres. Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade. CRSP remains highly shorted, with 20% of shares outstanding sold short. Considering Crispr's secular growth in the long term, perhaps short sellers are betting on near-term negative catalysts. Vertex is exploring an alternative to using Busulfan, which is used to clear out existing patient stem cells; finding a less toxic agent could increase Casgevy's patient population to 150k. Read the full article on Seeking Alpha
Seeking Alpha • Aug 14

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Summary CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns. CRISPR's partnership with Vertex Pharmaceuticals mitigates some operational risks associated with gene therapy. Given the uncertainties, CRISPR Therapeutics stock remains a "hold" until clearer commercial success is evident. Read the full article on Seeking Alpha
Seeking Alpha • Aug 07

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Summary Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey involves a lengthy process with no revenue recognition until the end, but the therapy has shown high effectiveness in clinical studies. Crispr Therapeutics and Vertex are working on reducing preconditioning burden for Casgevy patients and exploring the potential of in vivo therapies for the future. Crispr made a net loss of $126.4m in Q2, but retains ~$1.7bn of cash, and its pipeline contains assets potentially approvable near term, plus two in-vivo programs offering breakthrough treatments. In my view, Crispr Therapeutics is remains a highly attractive company to invest in with a clear path to >41bn in annual revenues. Read the full article on Seeking Alpha
Seeking Alpha • Jul 13

Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle

Summary CRSP has achieved the highly coveted regulatory approval for its gene editing technology as therapy for Severe Sickle Cell Disease and Thalassemia. However, with revenue recognition only likely from Q4'24 or Q1'25 onwards, readers may want to temper their near-term expectations. At the same time, CRSP does not own the patent of its gene editing technology, with a patent battle still occurring between the two groups of inventors. As the stock continues to trade sideways since November 2021, we believe that its intermediate-term investment thesis is likely tied to its swing trade potential. CRSP is likely to remain volatile as well, attributed to the elevated short interest and intense insider selling, with it only suitable for investors with higher risk tolerance. Read the full article on Seeking Alpha
Seeking Alpha • Jul 07

Crispr Therapeutics: Beaten Down But Not Broken

Summary CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in the early stages, with Casgevy being the only commercially approved program. CRSP aims to expand its TAM and reach sustainable profitability over time. I argue why CRSP is close to an inflection point, suggesting buyers should consider capitalizing on its recent pessimism. Read the full article on Seeking Alpha
Seeking Alpha • Jun 10

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Summary CRISPR Therapeutics’ new gene-editing protocol gives it a legitimate claim to be the future of medicine. That powered the stock back in 2020-21. But at some point, it’ll take revenues and profits, not futurism to justify stock ownership. The in-progress launch of Casgevy, a gene-editing treatment for Sickle Cell Disease suggests that transition is closing in. But that’s still getting off the ground, making numbers hard to project, and leaving room for disappointments. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

Summary CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia, impacting its market adoption. The initial commercial rollout of gene therapies requires the establishment of authorized treatment centers, and CRISPR has already set up more than 25 globally. Despite Q1 revenue missing estimates, the company is controlling expenses and shows a healthy balance sheet with a solid cash runway. The commercial success of Casgevy hinges on long-term patient outcomes and will likely face limited early adoption. Updated investment recommendation: change from "sell" to "hold" due to recent stock valuation adjustments and prudent expense management. Read the full article on Seeking Alpha
Seeking Alpha • May 09

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg

Summary Crispr Therapeutics AG reported a net loss of $116.6 million in Q1 2024, but is expected to have significant earnings in the future as its gene editing therapy Casgevy gains commercial sales. Casgevy is approved to treat Sickle Cell Disease and Transfusion Dependent Beta Thalassemia in the U.S., EU, and other territories, with the potential to "functionally cure" patients. Crispr Therapeutics has a strong balance sheet, a diverse pipeline, and the potential to expand its reach to a larger patient population in the future. Its three targets ex-Casgevy are Type 1 diabetes, immuno-oncology, and in-vivo gene therapy - some compelling progress is being made in each field. In short - what's not to like? One day, Crispr Therapeutics will get the valuation upgrade it deserves. Read the full article on Seeking Alpha
Seeking Alpha • May 03

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

Summary Crispr Therapeutics AG stock has plunged deep into a bear market. The FOMO attributed to Crispr's Casgevy approvals is likely dissipated. Crispr has an expanding early-stage portfolio. Crispr is also gaining traction to improve Casgevy's safety profile. Crispr Therapeutics stock is also no longer overvalued, as late buyers likely rushed out quickly. The stock's selling intensify has also slowed, allowing dip-buyers an attractive opportunity to load up. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Crispr Therapeutics: Now Is The Time To Buy

Summary Despite recent FDA approvals for its groundbreaking gene editing technology, CRISPR Therapeutics' stock has experienced a decline in value. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR Therapeutics has managed financial risks through partnerships and has enough cash on hand to fund operations for at least 24 months. Read the full article on Seeking Alpha
Seeking Alpha • Mar 26

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Summary Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEVY in approved countries. Private insurers are showing interest in covering CASGEVY, providing further support for its commercial launch. Read the full article on Seeking Alpha
Seeking Alpha • Feb 22

Crispr Therapeutics: Cautiously Optimistic

Summary CRISPR Therapeutics has experienced significant growth in the past five years, with its stock price soaring and then stabilizing around $80. The company has achieved regulatory approval for its CRISPR-based therapy for sickle cell disease and beta-thalassemia and has a diverse pipeline targeting various diseases. Investing in CRISPR Therapeutics requires risk tolerance and a long-term perspective, as the road to commercial success is complex and uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Feb 01

Crispr Therapeutics: Investors Bet Against Casgevy Uptake

Summary Crispr Therapeutics recently received FDA approval for gene editing therapy, Casgevy for treating Sickle Cell Disease and Beta-Thalassemia. In this article I'll look at Casgevy's market potential and its commercialisation challenges. The cost of Casgevy, treatment cons, scalability and accessibility pose serious challenges for widespread adoption. Which may justify the high short interest in the stock. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Crispr Therapeutics: Commercial Validation Is The Next Step

Summary CASGEVY is expecting more approvals from various global regulatory bodies, potentially increasing the total addressable patients. The management team is attempting to make CASGEVY more accessible through an in-vivo solution. The concerns surrounding commercial launch risks are overshadowed by the potential of CRISPR Therapeutics. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry

Summary CASGEVY is a groundbreaking gene therapy, owned by CRISPR AG and Vertex specifically designed for the treatment of sickle cell disease. Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands out as the first FDA-approved therapy utilizing CRISPR/Cas9. CASGEVY’s approach involves modifying the patient’s own hematopoietic (blood) stem cells using CRISPR/Cas9 technology. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:CRSP - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2028592-170-1004911
12/31/2027145-372-232-21319
12/31/202636-479-380-22420
3/31/20264-569-426-400N/A
12/31/20254-582-371-345N/A
9/30/202538-488-328-302N/A
6/30/202538-468-351-325N/A
3/31/202538-386-308-306N/A
12/31/202437-366-145-143N/A
9/30/2024203-240-191-189N/A
6/30/2024202-266-127-122N/A
3/31/2024272-217-169-159N/A
12/31/2023371-154-272-260N/A
9/30/2023170-354-295-278N/A
6/30/2023170-416-363-343N/A
3/31/2023100-524-377-352N/A
12/31/20221-650-533-496N/A
9/30/202214-681-509-468N/A
6/30/202215-633-516-445N/A
3/31/2022915312414504N/A
12/31/2021915378457539N/A
9/30/2021902412465544N/A
6/30/2021902447502549N/A
3/31/20211-392-309-287N/A
12/31/20201-349-257-238N/A
9/30/202077-211-167-154N/A
6/30/2020289204555N/A
3/31/2020289464048N/A
12/31/201929067N/A57N/A
9/30/2019213-11N/A25N/A
6/30/20191-200N/A-128N/A
3/31/20192-185N/A-117N/A
12/31/20183-165N/A-96N/A
9/30/201835-117N/A-83N/A
6/30/201837-91N/A-79N/A
3/31/201840-75N/A-69N/A
12/31/201741-68N/A-70N/A
9/30/201711-51N/A-75N/A
6/30/201710-41N/A-71N/A
3/31/20177-36N/A-69N/A
12/31/20165-23N/A-53N/A
9/30/20163-53N/A33N/A
6/30/20162-44N/A40N/A
3/31/20161-31N/A51N/A
12/31/20150-26N/A59N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CRSP rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CRSP rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CRSP rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CRSP ( 65.2% all'anno) crescerà più rapidamente del mercato US ( 12.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CRSP ( 65.2% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che CRSP non sarà più redditizia tra 3 anni.

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/06 05:38
Prezzo dell'azione a fine giornata2026/07/02 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

CRISPR Therapeutics AG è coperta da 40 analisti. 20 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jack AllenBaird
William PickeringBernstein
Alec StranahanBofA Global Research